POINT OF CAREDIAGNOSTICS
POINT OF CAREDIAGNOSTICS
ADVANCEDTHERAPEUTICS
ADVANCEDTHERAPEUTICS
DISRUPTIVEHEALTH INTELLIGENCE
DISRUPTIVEHEALTH INTELLIGENCE
BIOPHARMA ADVISORY
BIOPHARMA ADVISORY
Our journey so far…
For over a decade, from the initial round of seed funding that enabled us to enter the clinical trials space in 2010, to the sale of our ongoing site operations in 2020, Vx Pharma has earned a reputation for integrity, innovation, and excellence.
Now, at the dawn of our second decade, the vision of our founder Dr. Mark Fyvie is of a leading contributor and pioneer, capitalising on the revolutionary ICT- and biotechnologies now disrupting the diagnostics, therapeutics, health intelligence, and clinical research sectors.
To achieve those aims, Vx Pharma has been fundamentally restructured, to enable us to sell, finish, and invent in our four selected focus areas.
Over the coming months, we will announce a range of exciting new projects, products and services, and welcome inquiries from investors, partners, and buyers.
First round of seed funding
Series ‘A’ VC round by Industrial Development Corporation
Build out of super-site operations at the Innovation Hub
Series ‘B’ VC round by Ampath TLC
Restructured business acquired by founder and sale of site operations
About Mark Fyvie (PhD, Cambridge University)
Mark Fyvie on Linkedin
Mark Fyvie is a biotechnology entrepreneur, the founder of Vx Pharma and currently its sole shareholder. Prior to Vx Pharma, Mark served as CEO and founding member of the Cape Biotech Investment Trust, funding and incubating VC investments in excess of $100 million in new life-science ventures. An internationally accredited business strategy consultant, Mark has helped develop commercial strategies for innovators in pharmaceutical, biotech, clinical research, and e-finance organisations, including FirstRand Bank, Liberty Health and Accenture. Mark serves on numerous boards and donates significant time to pro bono work in the South African innovation ecosystem.
OUR CLIENTS
